

2009

Cancer Summit On: Lung, Head & Neck, Breast, and Gastrointestinal and Colorectal Cancers

July 23-25, 2009

Hilton Oceanfront Resort, Hilton Head Island, SC

Program Directors

Chandra P. Belani, MD Mark Pegram, MD Axel Grothey, MD

Statement of Need/Program Overview: This program is intended to facilitate interaction among medical oncologists, radiation oncologists, surgical oncologists, nurses, pharmacists, physician assistants, and nurse practitioners interested in development of novel therapeutics for treatment of solid tumors such as lung, head & neck cancers, breast cancer, and gastrointestinal/colorectal cancers. This symposium will present data of most promising emerging agents currently in development for the treatment. There will be in-depth discussion of targeted therapies for solid tumors.

Target Audience: This symposium is directed primarily to medical oncologists, radiation oncologists, surgical oncologists, researchers, pharmacists, registered nurses, nurse practitioners, and physician assistants interested in new developments for treatment of solid tumors such as lung cancer, head & neck cancers, breast cancer, gastrointestinal cancers, and colorectal cancer. No specific skill or knowledge other than a basic training in oncology is required for successful participation in this activity. Fellows are also invited to attend.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and International Cancer Network. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: Postgraduate Institute for Medicine designates this educational activity for a maximum of 15.25 hours of *AMA PRA Category 1 Credit(s)*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Purpose: The purpose of this activity is to assist oncology healthcare professionals in the diagnosis, treatment, and management of patients with lung, head & neck, breast, and gastrointestinal/colorectal cancers.

Credit Designation: This educational activity for 15.4 contact hours is provided by Postgraduate Institute for Medicine (PIM).

Accreditation Statements: Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be mailed to you within three weeks (if applicable).

Pharmacist Continuing Education

Accreditation Statement: Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation: Postgraduate Institute for Medicine designates each day of this continuing education activity for credit from the Accreditation Council for Pharmacy Education as follows: Thursday, July 23, 2009: 5.3 contact hour(s) (0.53 CEUs) - Universal Activity Number 809-999-09-063-LO1-P; Friday, July 24, 2009: 4.8 contact hour(s) (0.48 CEUs) - Universal Activity Number 809-999-09-064-LO1-P; Saturday, July 25, 2009: 5.3 contact hour(s) (0.53 CEUs) - Universal Activity Number 809-999-09-065-LO1-P).

Jointly sponsored by International Lung Cancer Network and Postgraduate Institute for Medicine

First Name _____ Middle Initial _____ Last Name _____

Physician Pa-C Fellow NP PhD Pharmacist Industry Nurse Other

Specialty _____

Mailing Address _____

City _____ State _____ Zip Code _____

Phone _____ Fax _____ E-Mail _____

Registration Fee

Registration fee partially covers continental breakfast, lunch and syllabus book

Physicians \$75.00 Nurses, Pharmacists, others \$30.00
 Fellows No Registration Fee *Industry \$650.00

*Person(s) employed by for-profit organizations such as pharmaceutical and biotech companies, and financial institutions

Payment may be made: MC Visa Discover Amex Check

Credit Card Number _____ Expiration Date _____ Security code (AmEx on front) _____

Name and address as it appears on Credit Card _____

Signature _____

Register online at www.Internationalcancernetwork.com

Please make checks payable to International Lung Cancer Network. Mail checks to PO Box 116609, Carrollton, TX 75011-6609

To reserve your place for the meeting, please complete the registration form and fax it 443-267-0016. If you have any questions please call 972-939-6206 or

E-mail: knaidu@internationalcancernetwork.com

If you wish to be removed from this fax list, please call 1-877-637-6872, or fax 443-267-0016.

Fax registration to:
443-267-0016

Mail registration to:
PO Box 116609
Carrollton, TX 75011-6609

2009 Cancer Summit On: Lung, Head & Neck, Breast, and Gastrointestinal and Colorectal Cancers July 23-25, 2009 Hilton Oceanfront Resort, Hilton Head Island, SC

Lung, Head & Neck Cancers – Thursday - July 23, 2009

6:00 AM Continental Breakfast and Registrations
6:55 AM Welcome and Introductions

State of the Art Lectures

7:00 AM Non-Small-Cell Lung Cancer: Recent Advances and Changing Treatment Paradigms
7:20 AM Combined Modality Therapy for Lung, Head & Neck Cancers
7:40 AM Small Cell Lung Cancer: Recent Developments and Incorporation of Novel Agents
8:00 AM Panel Discussion

EGFR and VEGF Targeted Agents

8:20 AM Advanced and Metastatic Non-Small-Cell Lung Cancer: Implications of Bevacizumab, Cetuximab and Histology
8:40 AM EGFR Tyrosine Kinase Inhibitors and Monoclonal Antibodies: Present Status and Future Perspectives, Molecular Markers and Patient Selection
9:00 AM Other VEGF Targeted Agents and Multikinase Inhibitors in the Treatment of Lung Cancer
9:20 AM Panel Discussion
9:40 AM BREAK
9:50 AM Cooperative Group Strategies in Lung Cancers
10:10 AM Individualizing Chemotherapy and Targeted Therapy for Patients with Lung Cancer
10:30 AM Implications of Proteomics and Genomics in the Management of Lung Cancer
10:50 AM Panel Discussion

Emerging Novel Agents

11:10 PM Emerging Role of Targeted nab-Paclitaxel, Bortezomib, and HDAC Inhibitors in lung cancer
11:30 PM New Systemic Therapies for the treatment of Head & Neck Cancers
11:50 PM Emerging Novel Agents in Lung Cancer (Farletuzumab, TRAIL and mTOR Inhibitors, MEK Inhibitors, AKT Inhibitors, IGF-IR Antibodies, and Small Molecule Inhibitors)

12:10 PM Panel Discussion
12:30 PM Closing Remarks and Adjourn
12:35 PM LUNCH

Breast Cancer - Friday - July 24, 2009

6:00 AM Continental Breakfast and Registration
6:55 AM Welcome and Introductions

State of the Art Lectures

7:00 AM State of the Art: Breast Cancer Therapy 2009
7:20 AM Management of Women at High Risk of Breast Cancer
8:00 AM Molecular Profiling of Breast Cancer

Adjuvant and Hormonal Therapies of Breast Cancer

8:20 AM Optimizing Adjuvant Hormonal Therapy in Breast Cancer: Current Status
8:40 AM Strategies to Treat Bone Loss in Women With Breast Cancer
9:00 AM Predictive and Prognostic Markers for Response and Survival in Breast Cancer
9:20 AM Panel Discussion
9:40 AM BREAK

Targeting VEGF and EGFR in Breast Cancer

9:50 AM Role of VEGF and VEGFR Targeted Therapy for Breast Cancer

Radiation Therapy Approaches

10:10 AM New Insights into Optimizing Local Control in Breast Cancer
10:30 AM Accelerated Hypofractionated Breast Radiation Therapy: Safety and Efficacy Issues
10:50 AM Panel Discussion

Emerging Novel Agents and Supportive Therapy

11:10 AM Novel Biologic Agents with Clinical Promise in the Treatment of Breast Cancer
11:30 AM Therapeutic Intervention for Patients with Triple Negative Breast Cancer
11:50 PM Supportive Care in the Management of Breast Cancer: Therapy Related Toxicities
12:10 PM Panel Discussion
12:30 PM Closing Remarks and Adjourn
12:35 PM LUNCH

Gastrointestinal/Colorectal Cancers - Saturday – July 25, 2009

6:30 AM Continental Breakfast
6:55 AM Opening Remarks and Introductions

State of the Art Lectures

7:00 AM Chemotherapy for Advanced Colorectal Cancer: An Update
7:20 AM Adjuvant Chemotherapy for Colorectal Cancer: New Strategies
7:40 AM Predictive and Prognostic Markers in Colorectal Cancer Beyond KRAS
8:00 AM Novel Targets for Colorectal Cancer: New Horizons

Targeting Angiogenesis

8:20 AM Role of VEGFR Small Molecule Inhibitors in Colorectal Cancer
8:40 AM Large Molecule Angiogenesis Inhibitors: Clinical Data and Ongoing Trials in Colorectal Cancer
9:00 AM Administering Angiogenesis Inhibitors to Patients with Colorectal Cancer: Safety Issues
9:20 AM Panel Discussion
9:40 AM BREAK

Targeting the EGFR Pathway

9:50 AM Role of EGFR Inhibitors in the Treatment of Colorectal Cancer: Integrating with Chemotherapy
10:10 AM Update on Ongoing Clinical Trials with EGFR Inhibitors
10:30 AM Toxicities Associated with EGFR Inhibitors: Management Strategies
10:50 AM Panel Discussion

Advances in Gastrointestinal Malignancies

11:10 AM Advances in the Treatment Options for Hepatocellular Carcinoma
11:30 PM Update on Treatment Options for Esophageal, Gastric and Pancreatic Cancers
11:50 PM Surgery for Liver-Limited Metastases of CRC
12:10 AM Panel Discussion
12:30 PM Closing Remarks and Adjourn
12:35 PM LUNCH

Educational Grants:

This program is supported by educational grants from:

Abraxis Oncology Genentech BioOncology Bristol-Myers Squibb/ImClone Systems Abbott Pharmaceuticals

If you wish to be removed from this fax list, please call 1-877-637-6872, or fax 443-267-0016.